X4 Pharmaceuticals, Inc.
XFOR
$3.74
-$0.13-3.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,925.73% | 5,721.31% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,925.73% | 5,721.31% | -- | -- | -- |
| Cost of Revenue | 1,050.51% | 1,978.73% | -- | -- | -- |
| Gross Profit | 4,403.82% | 9,121.36% | -- | -- | -- |
| SG&A Expenses | -14.96% | 13.49% | 29.33% | 73.27% | 75.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.05% | 11.68% | 25.46% | 33.89% | 22.34% |
| Operating Income | 28.18% | 14.33% | 1.69% | -31.51% | -21.30% |
| Income Before Tax | -468.53% | -673.29% | 111.58% | 63.26% | 84.99% |
| Income Tax Expenses | 251.76% | 258.33% | 249.46% | 297.44% | 44.07% |
| Earnings from Continuing Operations | -467.43% | -678.36% | 111.32% | 62.98% | 84.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -467.43% | -678.36% | 111.32% | 62.98% | 84.92% |
| EBIT | 28.18% | 14.33% | 1.69% | -31.51% | -21.30% |
| EBITDA | 28.88% | 15.15% | 2.44% | -31.28% | -21.30% |
| EPS Basic | -294.26% | -671.05% | 110.85% | 69.37% | 89.36% |
| Normalized Basic EPS | 46.02% | -12.50% | 35.87% | -17.38% | 23.50% |
| EPS Diluted | -288.01% | -680.37% | 110.72% | 69.23% | 89.19% |
| Normalized Diluted EPS | 46.01% | -12.53% | 35.89% | -17.36% | 23.52% |
| Average Basic Shares Outstanding | 141.07% | 4.42% | 5.88% | 13.20% | 30.63% |
| Average Diluted Shares Outstanding | 141.07% | 4.48% | 6.04% | 13.25% | 30.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |